DONGWHA PHARM (000020) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, DONGWHA PHARM (000020) reported revenue of 496.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025496.4 billion KRW257 million KRW3.8 billion KRW[source]
2024464.9 billion KRW13.4 billion KRW2.1 billion KRW[source]
2023361.1 billion KRW18.8 billion KRW28.2 billion KRW[source]
2022340.4 billion KRW29.9 billion KRW21.6 billion KRW[source]
2021293.0 billion KRW22.5 billion KRW19.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025573.8 billion KRW185.3 billion KRW388.5 billion KRW[source]
2024533.3 billion KRW152.2 billion KRW381.1 billion KRW[source]
2023473.9 billion KRW98.2 billion KRW375.6 billion KRW[source]
2022429.9 billion KRW70.1 billion KRW359.8 billion KRW[source]
2021416.3 billion KRW72.0 billion KRW344.3 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
202515.7 billion KRW-41.2 billion KRW13.4 billion KRW[source]
2024-4.0 billion KRW-74.8 billion KRW31.4 billion KRW[source]
202329.2 billion KRW2.9 billion KRW5.9 billion KRW[source]
202229.2 billion KRW-43.3 billion KRW-12.0 billion KRW[source]
202136.0 billion KRW-25.4 billion KRW-8.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice